Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transthyretin Amyloidosis (ATTR) With Cardiomyopathy”

68 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 68 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06194825
What this trial is testing

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

Who this might be right for
Transthyretin Amyloid Cardiomyopathy
AstraZeneca 64
Early research (Phase 1)Study completedNCT04601051
What this trial is testing

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyWild-Type Transthyretin Cardiac Amyloidosis
Intellia Therapeutics 72
Not applicableLooking for participantsNCT05098665
What this trial is testing

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

Who this might be right for
Cardiac Amyloidosis
Richmond Research Institute 320
Not applicableLooking for participantsNCT05697861
What this trial is testing

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyWild-Type Transthyretin Cardiac Amyloidosis
Intellia Therapeutics 72
Testing effectiveness (Phase 2)Study completedNCT03458130
What this trial is testing

Study of AG10 in Amyloid Cardiomyopathy

Who this might be right for
Familial ATTR-CM (ATTRm-CM, or FAC)Wild-type ATTR-CM (ATTRwt-CM)
Eidos Therapeutics, a BridgeBio company 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT06260709
What this trial is testing

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Who this might be right for
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S 80
Testing effectiveness (Phase 2)Study completedNCT02292186
What this trial is testing

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 25
Not applicableLooking for participantsNCT06907186
What this trial is testing

An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Hereditary Transthyretin Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT07213583
What this trial is testing

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

Who this might be right for
Amyloid Transthyretin Cardiomyopathy
Neurimmune AG 35
Not applicableStudy completedNCT03812172
What this trial is testing

Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations

Who this might be right for
Amyloid Cardiomyopathy, Transthyretin-Related
Mathew S. Maurer, MD 646
Large-scale testing (Phase 3)Active Not RecruitingNCT06128629
What this trial is testing

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics 1,200
Large-scale testing (Phase 3)Enrolling By InvitationNCT06679946
What this trial is testing

Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 700
Not applicableLooking for participantsNCT07235462
What this trial is testing

Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

Who this might be right for
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Bayer 2,000
Large-scale testing (Phase 3)Not Yet RecruitingNCT07116473
What this trial is testing

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Who this might be right for
Amyloidosis in Transthyretin (TTR)Amyloidosis, FamilialAmyloid Cardiomyopathy+7 more
Eidos Therapeutics, a BridgeBio company 250
Large-scale testing (Phase 3)Active Not RecruitingNCT04153149
What this trial is testing

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 655
Not applicableEnded earlyNCT04424914
What this trial is testing

Global Prevalence of ATTR-CM in Participants With HFpEF

Who this might be right for
Transthyretin Amyloid CardiomyopathyHeart Failure With Preserved Ejection Fraction
Pfizer 347
Not applicableNo Longer AvailableNCT05505838
What this trial is testing

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT06539208
What this trial is testing

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin Amyloidosis PolyneuropathyTransthyrexin Amyloidosis Cardiomyopathy
YolTech Therapeutics Co., Ltd 31
Not applicableUnknownNCT05896904
What this trial is testing

Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction

Who this might be right for
Transthyretin Amyloid CardiomyopathyHeart Failure
Aarhus University Hospital Skejby 100
Post-approval studies (Phase 4)Not Yet RecruitingNCT07298044
What this trial is testing

Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Who this might be right for
Transthyretin Amyloid Cardiomyopathy
Bayer 50
Load More Results